Pimagedine
- Generic Name
- Pimagedine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- CH6N4
- CAS Number
- 79-17-4
- Unique Ingredient Identifier
- SCQ4EZQ113
- Background
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
- Indication
Investigated for use/treatment in diabetic kidney disease.
- Associated Conditions
- -
- Associated Therapies
- -
Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 34
- Registration Number
- NCT02099981
- Locations
- 🇺🇸
University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 30
- Registration Number
- NCT00180635
- Locations
- 🇬🇧
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom
Effect of Selective iNOS Inhibition During Human Endotoxemia
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT00184990
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 16
- Registration Number
- NCT00159380
- Locations
- 🇬🇧
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.